On January 23, 2025, the marketing registration application for Semaglutide Injection, submitted by Zhuhai United Bio-Pharmaceutical Co., Ltd., was officially accepted by the National Medical Products Administration (NMPA). This is the products variety declared by The United Laboratories following the company』s successful inclusion in the NMPA』s pilot program for segmented production of biological products.

Semaglutide is a long-acting GLP-1 analogue composed of 31 amino acids, administered once weekly via subcutaneous injection. In the human body, it mimics the function of GLP-1, significantly lowering blood glucose levels, promoting insulin secretion, and repairing pancreatic β-cells and other physiological functions. It is safe, effective, and convenient to use. Its development has important clinical significance and is expected to generate considerable social and economic benefits.